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Abstract 
 
Aim 
We assessed the effectiveness of 4th line mineralocorticoid receptor antagonists in 
comparison to other 4th line anti-hypertensive agents in resistant hypertension.  
Methods and Results  
We systematically searched Medline, EMBASE and the Cochrane library from database 
inception until January 2016. We included randomised and non-randomised studies that 
compared mineralocorticoid receptor antagonists to other 4th line anti-hypertensive agents in 
patients with resistant hypertension. The outcome was change in systolic blood pressure, 
measured in the office, at home or by ambulatory blood pressure monitoring. Secondary 
outcomes were changes in serum potassium and occurrence of hyperkalaemia. We used 
random effects models and assessed statistical heterogeneity using the I2 test and 
corresponding 95% confidence intervals.  
From 2,506 records, 5 studies met our inclusion criteria with 755 included patients. Two 
studies were randomised and three were non-randomised. Comparative fourth line agents 
included bisoprolol, doxazosin, furosemide and additional blockade of the renin angiotensin-
aldosterone system. Using data from randomised studies, mineralocorticoid receptor 
antagonists reduced blood pressure by 7.4mmHg (95% CI 3.2 – 11.6) more than the active 
comparator. When limited to non-randomised studies, mineralocorticoid receptor antagonists 
reduced blood pressure by 11.9mmHg (95% CI 9.3 – 14.4) more than the active comparator.  
Conclusion 
On the basis of this meta-analysis, mineralocorticoid receptor antagonists reduce blood 
pressure more effectively than other 4th line agents in resistant hypertension. Effectiveness 
stratified by ethnicity and comorbidities, in addition to information on clinical outcomes such 
as myocardial infarction and stroke now needs to be determined.  
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Introduction 1 
 2 
Hypertension is a leading cause of mortality worldwide. It occurs in 1 out of 4 people 3 
and is responsible for 9.4 million deaths annually.1, 2 Of those affected, approximately 14% 4 
are said to have resistant hypertension (RH)3, defined as blood pressure (BP) that remains 5 
≥140/90mmHg despite being treated with maximum doses, or best tolerated doses, of three or 6 
more antihypertensive agents, one of which should be a diuretic.4 The prevalence of RH is 7 
equally distributed between men and women, but is more common in older people (mean age 8 
60yrs).3 Those with diabetes and chronic kidney disease (CKD), along with those who are 9 
obese, are over-represented in the RH population.5 Patients with RH generally have a poorer 10 
prognosis than those whose hypertension is controlled, with a 50% increased risk of a 11 
cardiovascular event.6  12 
The pathophysiology of RH remains poorly understood. Once adherence and white 13 
coat hypertension have been ruled out, over activation of the renin-angiotension-aldosterone 14 
system (RAAS), over activation of the sympathetic nervous system, sodium retention leading 15 
to volume expansion and/or vascular stiffening have all been suggested as potential 16 
pathological mechanisms.7-10 Given the mixed pathologies and a historical dearth of evidence 17 
for the treatment of RH11, current clinical guidance from international sources is slightly 18 
discordant.  For example, NICE guidelines in the UK suggest the use of either spironolactone 19 
(a mineralocorticoid receptor antagonist (MRA) with potassium sparing diuretic activity),  or 20 
increasing the dose of the thiazide diuretic in the case of high serum potassium as potential 21 
4th line options on top of an angiotensin-converting enzyme inhibitor (ACEI)/angiotensin 22 
receptor blocker (ARB), a calcium channel blocker, and a diuretic.4 The European Society of 23 
Hypertension/European Society of Cardiology guidelines refer to the use of fourth-line MRA, 24 
amiloride or an alpha-blocker. 12 In the USA, both the American Heart Association and the 25 
Eighth Joint National Committee guidance specify adding a beta-blocker or a MRA as fourth-26 
MRAs versus other 4th line agents in RH 
 
5 
 
line agents and/or seeking specialist advice. 13, 14  Despite these disparities, the general 27 
message from all is to enhance diuretic treatment. 4, 12-14 28 
Two recent systematic reviews have pointed to the effectiveness of MRAs versus 29 
placebo in lowering BP in those with RH.15, 16 While this is important evidence, it would now 30 
be useful to establish how MRAs compare to other potential 4th line agents.  31 
Hence, we assessed the effectiveness, in terms of systolic BP reductions, of MRAs in 32 
comparison to alternative 4th line anti-hypertensive agents in patients with RH.  33 
  34 
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Methods 35 
 36 
Data sources and searches 37 
We searched Medline, Embase and the Cochrane Library from inception up to January 2016 38 
with no language restriction. The search terms used in Medline were ‘resistant hypertension’ 39 
AND "Hypertension/drug therapy"[Mesh] AND "Antihypertensive Agents" 40 
[Pharmacological Action]; we constructed analogous searches in the other databases. We 41 
searched Clinicaltrials.gov for ongoing or completed trials of anti-hypertensive agents in RH. 42 
We also searched the reference lists of included articles and recent clinical guidelines. Where 43 
relevant abstracts were found without corresponding full papers, we contacted study authors 44 
for full text papers. If a full text paper did not exist at that time, the record was excluded. We 45 
also contacted study authors to clarify any questions on their reported results.  46 
Study selection 47 
Definition of RH 48 
We included studies that defined RH as systolic BP ≥140mmHg despite being on ≥3 anti-49 
hypertensive agents. 50 
Study types 51 
Full texts of both randomised studies and non-randomised studies were eligible for inclusion. 52 
Letters, editorials and opinion pieces were excluded.  53 
Intervention and comparator 54 
The intervention was the addition of an MRA. The comparator was the addition of an 55 
alternative fourth-line anti-hypertensive agent. There was no restriction on agent, dose, 56 
duration of treatment or length of follow up. Studies that examined drugs that are not 57 
available on the market or not currently being tested in phase 2 or phase 3 trials were 58 
excluded.  59 
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Outcome 60 
The outcome was change in systolic BP in the intervention group relative to the comparator 61 
group. We used systolic BP, as opposed to both systolic and diastolic BP for two reasons. 62 
First, because systolic hyperetnsion is much more common in populations aged >50yrs than 63 
diastolic BP.17 Second, because systolic hypertension contributes more to the global 64 
cardiovascular disease burden than diastolic hypertension.17 There were no restrictions on 65 
how BP was measured; office, home or ambulatory blood pressure monitoring (ABPM) 66 
measurements were all included. In studies where more than one type of measurement was 67 
reported, ABPM was the preferred outcome for inclusion in the meta-analysis. Secondary 68 
outcomes included mean changes in serum potassium and the number of cases of 69 
hyperkalaemia in each treatment group.  70 
Data extraction and quality assessment 71 
SJS carried out the searches. After exclusion of duplicates and irrelevant titles and abstracts, 72 
four study authors (SJS, AR, RM and KM) independently assessed full texts for eligibility, 73 
and carried out data extraction and quality assessment in duplicate. Any differences of 74 
opinion were discussed and a third reviewer was available to arbitrate any issues that 75 
remained unresolved. We used a standardised data extraction form to collect information for 76 
each study on: the definition of RH used, including whether due consideration was given to 77 
white coat hypertension, adherence and secondary causes of hypertension; the type of study 78 
design and analysis used; and details on population characteristics for example, number of 79 
people included, mean age, proportion of females, mean body mass index (BMI), proportion 80 
of diabetic patients and mean estimated Glomerular Filtration Rate (eGFR). We extracted 81 
detailed data on baseline systolic BP, systolic BP at the end of follow up and change in 82 
systolic BP between the treatment arms for each study along with information on how BP 83 
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was measured. We collected adverse event data specifically for mean changes in serum 84 
potassium and hyperkalaemia.  85 
We assessed the quality of included studies using a modified Downs and Black checklist, 86 
which can be used for randomised studies and non-randomised studies.18 This checklist 87 
assesses quality across four domains: internal validity (bias and confounding), external 88 
validity and general quality of study reporting. Included studies were scored out of a potential 89 
21 points across these four domains.   90 
Data synthesis and statistical analysis 91 
We used the difference in mean reductions in systolic BP between treatment arms and the 92 
standard error in DerSimonian-Laird random effects models. Statistical heterogeneity was 93 
assessed using the I2 test and corresponding 95% confidence intervals estimated using the 94 
formula proposed by Higgins and Thompson.19 An I2 threshold of >60% indicated substantial 95 
heterogeneity. We analysed randomised and non-randomised studies separately. We did not 96 
formally test for the presence of publication bias due to the small number of included 97 
studies.20 Rather, we visually inspected the funnel plot. Secondary outcomes were 98 
qualitatively assessed.  99 
Sensitivity analyses 100 
Three methods of measuring BP were reported in the included studies; 1) office BP, 2) home 101 
BP and 3) ABPM. We conducted sensitivity analyses to assess whether combining different 102 
types of BP measurements in a meta-analysis gave substantially different result. We ran all 103 
analyses in Revman Version 5.3.21 We referred to Preferred Reporting Items for Systematic 104 
Reviews and Meta-Analyses (PRISMA) guidelines for reporting (Supplementary Information 105 
1).22 106 
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Results 107 
From 2506 citations, after exclusion of duplicates and irrelevant titles, 22 full texts were 108 
assessed for eligibility. Seventeen of these were excluded (Figure 1). Thus, five articles were 109 
included in the review.8, 23-26  110 
 111 
          112 
 113 
 114 
 115 
 116 
 117 
 118 
 119 
 120 
 121 
 122 
 123 
 124 
*Insert Figure 1* 125 
*Gap in text maintained above to preserve order of referencing* 126 
 127 
This included 755 patients with a mean age of 62 years and 30% female. Diabetes was highly 128 
prevalent at 45.6%, while eGFR was 83.9 ml/min, likely due to exclusion of patients with 129 
chronic kidney disease in some studies.8, 23, 25, 26 Mean BMI was 30.7 kg/m2 (Table 1). 130 
 131 
*Insert Table 1* 132 
 133 
16 full texts excluded:  
2 were letters27, 28  
4 were abstracts and we could not obtain a full paper29-32 
6 did not have intervention/control groups that met our inclusion criteria33-38 
2 did not meet our definition of RH39, 40 
2 reported results not amenable to inclusion in meta-analysis41, 42 
1 comparator drug no longer being developed43 
Number of imported records 
N= 2506 
Number of unique records 
N= 2030 
Remove duplicates 
n= 476 
Remove irrelevant 
titles and abstracts 
n= 2008 
Number of full texts 
N=22 
Number of included texts 
N= 6 
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Of the included studies, two were randomised controlled trials26 23 and three were non-134 
randomised24, 25 8  The intervention was spironolactone in all studies. The comparator drugs 135 
included doxazosin, bisoprolol, furosemide and additional RAAS blockade (Table 2). 136 
*Insert Table 2* 137 
There was substantial heterogeneity across the included studies in terms of how RH was 138 
defined and identified. Four studies referred to adherence to medication regimen before 139 
including patients as RH cases, but the reported detail on how this was examined was 140 
variable.8, 24-26 Bobrie et al.referred to adherence measurement during the study by pill count, 141 
but the threshold for adherence was not reported.23 The results of on treatment adherence 142 
assessment by urinalysis in the PATHWAY-2 trial is yet to be published.26 One study did not 143 
clearly define the BP thresholds used to define RH8 and two studies did not define how long a 144 
patient should be on 3 or more anti-hypertensive agents before being defined as having RH.8, 145 
25  146 
Two studies measured the outcome, systolic BP, both in the office and with ABPM 147 
monitoring 8, 23, one study each used office and ABPM monitoring respectively24, 25 and one 148 
study used home monitoring and office measurements.26  Follow up ranged from eight weeks 149 
to six months.  150 
Non-randomised studies were of much lower quality than randomised studies (Table 3). 151 
They achieved lower scorings on internal validity due to baseline characteristics being non-152 
comparable, statistical tests that did not account for confounding, not accounting for losses to 153 
follow up, not being adequately powered and not tracking adherence to the intervention or 154 
comparator drug.  155 
*Insert Table 3* 156 
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Results of meta-analysis 157 
We included two studies, including a total of 502 patients, in a meta-analysis of randomised 158 
studies. Using a random effects model, the overall pooled estimate for reduction of systolic 159 
BP by MRAs was 7.4mmHg (95% CI 3.2 – 11.6) more than the active comparator (Figure 160 
2a). Heterogeneity was measured as I2 = 76% (95% CI 0 – 95.5). There was one ABPM 161 
measurement in this analysis23 and one home measurement.26 162 
 163 
*Insert Figure 2A and 2B* 164 
 165 
We included three studies, including a total of 253 patients, in a meta-analysis of non-166 
randomised studies. Using a random effects model, the overall reduction in systolic BP was 167 
11.9mmHg (95% CI 9.3 – 14.4) more in spironolactone users than the active comparator 168 
(Figure 2b). Heterogeneity was measured as I2 = 0% (95% CI 0 - 40). There were two 169 
ABPM measurements8, 25 in this analysis and one office measurement.24 170 
 171 
Sensitivity analyses 172 
Office measurements in non-randomised studies 173 
In the main analysis using randomised and non-randomised studies, ABPM measurements 174 
were included where reported. In a sensitivity analysis, we included office BP, where 175 
reported, to assess the influence of measurement types on pooled results. For randomised 176 
studies, this analysis included two office BP measurements as opposed to one ABPM 177 
measurement23 and one home measurement in main analysis.26 Using a random effects 178 
model, the overall effect measure estimated that spironolactone reduced systolic BP by 179 
7.3mmHg (95% CI 0.9 – 13.8) more than the active comparator (Figure 3a). Heterogeneity 180 
was measured as I2 = 87% (95% CI 24.8 -97.8).  For non-randomised studies, the sensitivity 181 
analysis included two office BP measures8, 24 and one ABPM measurement.25  Using a 182 
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random effects model, the overall effect measure estimated that spironolactone reduced 183 
systolic BP by -13.4mmHg (95% CI 8.4 – 18.3) more than the active comparator (Figure 184 
3b). Heterogeneity was measured as I2 = 66% (95% CI 0 – 94).  185 
*Insert Figure 3* 186 
 187 
Changes in serum potassium and hyperkalaemia 188 
All five included studies reported changes in serum potassium or cases of hyperkalaemia.8, 23-189 
26 From Table 4, there were 12 cases of hyperkalaemia in 424 patients treated with MRAs, in 190 
comparison to 0 events in 471 patients treated with another fourth-line agent.  Mean serum 191 
potassium values increased to a greater extent in patients treated with MRAs than patients 192 
treated with another fourth-line agent (Table 4).  193 
 194 
*Insert Table 4* 195 
 196 
Publication bias 197 
There was some visual evidence of asymmetry in the funnel plot, suggesting a small study 198 
bias (Supplementary Information 3).  199 
MRAs versus other 4th line agents in RH 
 
13 
 
Conclusions 200 
This meta-analysis, encompassing five separate studies and 755 patients, found that when 201 
MRAs were compared with another fourth-line agent or strategy in the treatment of RH, 202 
MRAs achieved larger reductions in systolic BP, in the order of 7 to 12mmHg.  203 
Three previous reviews have indicated the effectiveness of MRAs versus placebo, in 204 
addition to its’ safety.15, 16, 44 The reduction in systolic BP achieved by MRAs in previous 205 
reviews averaged at approximately 20mmHg. This is roughly double the reduction in BP 206 
shown in our review. This difference was not unexpected considering we included studies 207 
with an active comparator only, whereas previous reviews included studies where placebo 208 
was the comparator group. Whether this magnitude of reduction in systolic BP will translate 209 
to a decrease in cardiovascular outcomes in patients with RH remains to be examined. It 210 
might be reasonably expected that clinical relevance is likely given recent evidence that, in a 211 
general hypertensive population, a 10mmHg reduction in systolic BP was associated with an 212 
approximate 20% reduction in risk of cardiovascular and coronary heart disease events, and 213 
an approximate 30% reduction in risk of  stroke and heart failure.45  214 
Our sensitivity analysis for randomised studies demonstrated little difference in the 215 
magnitude of reductions gained in systolic BP when measured using office measurements 216 
versus home or ABPM measurements. The randomised nature of these studies likely 217 
preserved the relative difference between treatment arms. In contrast, when the majority of 218 
non-randomised studies reported office BP rather than the majority reporting ABPM 219 
measurements larger reductions in systolic BP were found (-13.8mmHg versus -11.9mmHg). 220 
Although the difference in these findings was not significant, the trend towards greater 221 
reductions via office measurements is in line with current knowledge on the contribution of 222 
white coat hypertension in RH, and indeed in hypertension more broadly.46, 47 This finding 223 
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also points to the importance of home BP or ABPM monitoring in detecting BP levels that 224 
are ultimately predictive of clinical events and mortality.48 225 
In all studies, where reported, the average increase in serum potassium was larger in the 226 
MRA group compared with other 4th line agents.  The magnitude of mean changes appeared 227 
to be larger in non-randomised studies than randomised studies. Similar findings were 228 
reported in a recent systematic review whereby the increase in serum potassium, found in 229 
non-randomised studies, was 0.46mmol/L higher than in placebo treated patients.16 However, 230 
in randomised studies, the mean change between the groups was 0.15mmol/L, and this was 231 
non-significant.16 A second review, encompassing a meta-analysis of mixed randomised and 232 
non-randomised studies, showed an increase of 0.33mmol/L (95% CI, 0.27-0.39) in serum 233 
potassium in users of MRAs.15   234 
Our review also points to an increased number of hyperkalaemia-related events in patients 235 
treated with MRAs in comparison to patients treated with other 4th line agents. The 236 
systematic review authored by Dahal et al. reports an event rate of 46/1000 for hyperkalaemia 237 
in patients treated with MRAs in comparison to placebo, but this was solely in non-238 
randomised studies and the same finding of increased risk was not found in randomised 239 
studies.16 The difference in biochemical parameters reported by randomised and non-240 
randomised studies may reflect differences in how patients are monitored in different study 241 
settings. For example, in clinical trials frequent follow up visits allow opportunity to identify 242 
changes in serum potassium before advancement to hyperkalaemia. In contrast, non-243 
randomised studies are often conducted in routine care and reflect the true 244 
frequency/infrequency of laboratory testing, and thus the real world safety implications of 245 
treatments for patients.49 Discordant findings between randomised and non-randomised 246 
studies aside, the risk of hyperkalaemia related events, especially in people using both and 247 
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ACEI/ARB and spironolactone, remains a worry and frequent lab monitoring is 248 
recommended.50   249 
Our review provides evidence that on average, MRAs are more efficient in lowering 250 
systolic BP than other potential fourth-line agents such as bisoprolol, doxazosin and 251 
additional RAAS blockade.  This may be explained by the main pathophysiology associated 252 
with RH; volume expansion secondary to salt sensitivity/retention.10 253 
MRAs’ antagonism of aldosterone at the distal tubule, resulting in the removal of sodium 254 
in exchange for potassium thus increasing diuresis, reduces the problem of volume 255 
expansion.51  While the use of an ACEI or an ARB should block the production of 256 
aldosterone at an earlier stage in the RAAS, a phenomenon referred to as “aldosterone 257 
synthesis escape” requires direct blockade of aldosterone at the mineralocorticoid receptor to 258 
ensure lowering of blood pressure, thus providing a functional and productive role for 259 
spironolactone on top of other anti-hypertensive agents.52  260 
While other pathophysiologies can be implicated in RH, such as over-activation of the 261 
sympathetic nervous system10, the success of MRAs in RH may be due to volume expansion 262 
being the most prevalent mechanism underpinning the disease. A second reason for the 263 
benefit of MRAs above other 4th line agents is that, in addition to its’ action at the distal 264 
tubule, there is evidence to suggest that MRAs also work on the vasculature reducing BP by 265 
other mechanisms. For example, spironolactone has been found to increase vascular 266 
compliance in rats52, inhibit vasoconstriction in the arterioles 53and eplenerone has been 267 
found to improve endothelial function and inhibit Rho-associated kinases, which are involved 268 
in the contracture of vascular smooth muscle cells.54  269 
We observed several important sources of heterogeneity between the studies included in 270 
the review, for example; study authors rarely discussed how long their included populations 271 
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were on ≥3 anti-hypertensive agents before being classified as RH.  Not all studies sought to 272 
exclude white coat hypertension, nor did all studies examine insufficient adherence to anti-273 
hypertensive medication regimens during the study. This points to a requirement for a more 274 
stringent application of a standardised definition of resistant hypertension to avoid mixed 275 
samples of patients, leading to results that do not apply to the actual RH population. We 276 
noted some evidence of publication bias in the funnel plots. This was likely associated with 277 
poor methodological quality in the included non-randomised studies.55 278 
Our review has multiple strengths. First, we used a comprehensive search strategy 279 
yielding more than 2,500 records that we screened for inclusion. Second, we carried out study 280 
selection and data abstraction in duplicate to enhance the reliability of our findings. Third, 281 
this review provides a quantitative estimate of the effectiveness of MRA in comparison to 282 
other antihypertensive agents that could be used as fourth-line agents in RH, improving on 283 
other reviews that examined placebo as the comparison group.15 16, 44 Information on 284 
comparative effectiveness is constructive in that MRAs will not suit every patient with RH, 285 
for example in patients where a drug-drug interaction is expected or adverse events such as 286 
hyperkalaemia could reasonably occur.56 In such cases, information on the effectiveness of 287 
alternative pharmacologic options is required.  288 
Our review is limited in that it we did not assess individual level patient data. This would 289 
have allowed comprehensive subgroup analyses according to sex, age, diabetes status and 290 
renal function. The number of included studies in each meta-analysis was low. While more 291 
studies would have been preferable, it was still appropriate to carry out a meta-analysis. This 292 
was for reasons of transparency in the processes employed to reach a summary conclusion, 293 
and also because combining the results of studies added information beyond what was held in 294 
each individual study.57 A small number of included studies meant it was also challenging to 295 
accurately assess between-study heterogeneity. We attempted to ameliorate this limitation by 296 
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presenting 95% confidence intervals around the point estimate for I2 value.58,19 A further 297 
limitation is that the included studies were of varying quality. Non-randomised studies, in 298 
particular, often include an amount of confounding by indication, and the studies included in 299 
this review mostly used methodology not designed to address this, for example simple 300 
statistical analyses such as t-tests or Wilcoxon tests. Nonetheless, a meta-analysis of these 301 
studies was useful for the reasons of transparency and combining information as mentioned 302 
above.57 In addition, for a topic area where not many trials exist, it seems efficient to use all 303 
available evidence, with due appreciation for its’ limitations. The non-randomised studies we 304 
included found a similar overall effect to the randomised studies in this review suggesting 305 
confounding may not have been strong in this instance. This is likely to arise if the choice 306 
between different drugs is not driven by strong evidence and could indicate a perception of 307 
equipoise in many cases. It therefore appears that observational data may be of further use for 308 
investigating the comparative effects of different drug choices for RH. However, our nuanced 309 
summary of deficits noted in the literature should be addressed in future studies. 310 
While quantitative estimates of the benefits of MRAs in reducing BP in RH are now 311 
available, it would be helpful to stratify these changes in BP by patient characteristics such as 312 
ethnicity, and co-morbidities such as diabetes and renal function.15, 59 Future meta-analyses 313 
might endeavour to stratify by different classes of comparator agents, e.g., beta-blockers, 314 
diuretics and alpha-blockers to enable a more nuanced understanding of the comparative 315 
effectiveness of MRA. It is now important that an assessment of effects on clinical outcomes 316 
such as stroke and myocardial infarction is conducted. A rough calculation using information 317 
on outcome parameters from the SPRINT trial indicates that an RCT of approximately 15,000 318 
patients with 2 years follow up would be required to detect a 20% difference in 319 
cardiovascular outcomes for RH patients on spironolactone versus other 4th line agents.60 The 320 
practical challenges of recruiting this number could be sidestepped by conducting a well-321 
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designed and appropriately powered observational study. From the data presented in this 322 
study, it appears that observational studies can detect similar effect sizes to randomised trials 323 
in studies of RH, and thus, if designed appropriately offer a useful and practical way forward.   324 
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Figures 
 
 
Figure 1: Flowchart of results 
 
Figure 2A (upper panel): Meta-analysis of changes in systolic BP for randomised studies. 
Figure 2B (lower panel): Meta-analysis of changes in systolic BP for non-randomised 
studies 
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Figure 3: Meta-analysis of changes in systolic BP for non-randomised studies, using office 
BP measurements where reported 
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Tables 
Table 1: Description of participants in included studies 
 
eGFR – estimated Glomerular Filtration Rate, ABPM – Ambulatory Blood Pressure 
Monitoring, BMI – Body Mass Index, BP –Blood Pressure 
^GFR calculated with MDRD equation, #GFR calculated with unknown method, *GFR 
calculated with CKD EPI equation ~Creatinine Clearance given  
NR- not reported 
 
 
 
 
 
 n 
Mean 
Age 
% 
Female 
% 
Diabetes  
Mean 
eGFR 
% 
Smoking 
Mean 
BMI 
Mean 
no. of 
drugs 
Baseline 
systolic 
BP 
Outcome 
measurement 
1 
Outcome 
measurement 
2 
Randomised studies 
Bobrie 
201223 167 55.87 24.51 19.96 83.44^ 51.91 28.36 3.00 146.00 24 hr ABPM Office BP 
Williams 
201526 335 61.40 31.00 41.00 91.00# 7.80 NR  NR 147.60 Home BP Office BP 
Non-randomised studies 
Alvarez-
Alvarez 
20108 42 66.85 50 NR 83.08~ 10.3 31.79 4.10 141.00 24 hr ABPM Office BP 
Rodilla 
200924 181 65.49 29.00 76.09 76.09^ 9.41 32.45 NR 165.43 Office BP Office BP 
Verdalles 
201525 30 66.30 30.00 56.70 55.85* NR 31.35 3.80 162.80 24 hr ABPM  NR 
Total 755 61.65 30.1 45.64 83.92 18.51 30.68 3.29 151.76  ~  ~ 
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Table 2: Description of included studies 
RCT – randomised controlled study, RAS – renin-angiotensin system, RH – resistant hypertension, ABPM- ambulatory blood pressure monitoring.  
ACE – angiotensin converting enzyme, ACEI/ARB - angiotensin converting enzyme inhibitor/angiotensin receptor blocker
Study Study Design Location n Intervention Comparator 
Assessment of 
white coat 
hypertension 
Assessment of 
adherence prior to 
inclusion 
Assessment 
of adherence 
during trial Follow up 
Randomised studies 
Bobrie 201223 RCT France 165 Nephron blockade: spironolactone 25mg, 
followed by furosemide 20mg/day, 
titrated to 40mg/day, followed by 
addition of amiloride. 
Block of RAS: 
ramipril5mg/day, titrated to 
ramipril 10mg/day, followed 
by bisoprolol 5mg/day titrated 
to bisoprolol 10mg/day 
Yes No details Yes - pill 
counts 
12 weeks 
Williams 201526 RCT UK 335 Spironolactone (25mg-50mg) Bisoprolol (5 – 10mg) or 
doxazosin (4-8mg) 
Yes Yes - pill counts and  
directly observed 
therapy 
Urinalysis 12 weeks 
Non-randomised studies 
Alvarez-Alvarez 20108 Prospective 
crossover 
Spain 39 Spironolactone 25mg increased to 50mg Addition of ACEI/ARB Yes No details No details 12 weeks 
Rodilla 200924 Cohort study Spain 181 Spironolactone 14mg (average) Doxazosin 4mg (average) Yes Yes, but no details how No details 3 months for 
spironolactone 
and 6 months 
for doxazosin 
Verdalles 201525 Cohort study Spain 30 Spironolactone 25mg Furosemide 40mg Yes Yes, but no details how No details 6 months 
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Table 3: Description of quality of included studies 
 
 
 
 
Notes: A detailed scoring sheet along with description of quality assessment form is 
included in Supplementary Information 2.
 
Internal Validity - 
Bias 
Internal Validity - 
Confounding 
External 
Validity 
Adverse event 
reporting 
Randomised studies 
Bobrie 201223 6.5/8 6/10 2/2 1/1 
Williams 201526 
 
8/8 8/10 1/2 1/1 
Non-randomised studies 
Alvarez-Alvarez 20108 5/8 4/10 0/2 1/1 
Rodilla 200924 3/8 3/10 0/2 1/1 
Verdalles 201525 5/8 4/10 0/2 1/1 
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Table 4: Number of cases of hyperkalaemia and mean changes in serum potassium in patients treated with spironolactone and other 4th line 
agents 
 Spironolactone Other 4th line agents 
 
Cases of 
hyperkalaemia 
Mean change in serum 
potassium (SE) 
Cases of 
hyperkalaemia 
Mean change in serum 
potassium (SE) 
Bobrie 201223 3/85 0.30 (0.80) 0/82 0.00 (0.13) 
Williams 201526 6/285 0.42* 0/335 0.15^*/0.08#* 
Subtotal events for randomised studies 9/370 ~ 0/417 ~ 
     
Alvarez-Alvarez 20108 1/39 0.53 (0.09) 0/39 0.09 (0.08) 
Rodilla 200924 NR 0.41 (0.05) NR 0.11 (0.08) 
Verdalles 201525 2/15 NR 0/15 NR 
Subtotal events for non-randomised studies 3/54 ~ 0/54 ~ 
Total events 12/424 ~ 0/471 ~ 
Notes: NR = not reported. Verdalles reported two cases of “mild” hyperkalaemia defined as serum potassium 5.0-5.5mmol/L. * 
*Variance for serum potassium changes not reported. ^Bisoprolol as comparator. #Doxazosin as comparator. 
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Supplementary Information 1 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Title page 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic 
review registration number.  
1 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3+4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and 
study design (PICOS).  
4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
No, attempted to register 
at PROSPERO however, 
our work had begun so 
our protocol could not be 
included in PROSPERO 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication 
status) used as criteria for eligibility, giving rationale.  
5+6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in 
the search and date last searched.  
5+6 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  5 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-
analysis).  
5+6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
5+6 
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Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
7 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-
specified.  
7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally 
with a flow diagram.  
Figure 1 and page 8 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
Table 1 and page 9 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Table 2 and page 10 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
Figures 2 and 3.  
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Figures 2, and 3 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Appendix 3 and page 14.  
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  Figure 3 and Table 3, also 
pages 13 and 14.   
DISCUSSION   
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  6 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or 
outcome level), and how this information is to be used in any data synthesis.  
6+7 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each 
meta-analysis.  
7 
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Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., 
healthcare providers, users, and policy makers).  
15-18 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, 
reporting bias).  
Pg 18 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  Pg 18 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review.  
Pg 19 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
Page 2 of 2  
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Supplementary Information 2 
Quality Assessment 
 
Table S2: A detailed scoring across quality indicators as assessed using a modified Downs and Black quality assessment tool 
  Internal Validity - Bias Internal Validity - Confounding External Validity Misc - study quality Total 
 Question # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 21 
Alvarez-Alvarez 0 0 1 1 1 1 0 1 1 1 1 0 0 0 1 0 0 0 0 0 1 10 
Bobrie 0 1 1 1 1 1 0.5 1 1 0 1 1 1 1 0 1 0 0 1 1 1 15.5 
Rodilla 0 0 1 0 0 1 0 1 1 0 0 1 1 0 0 0 0 0 0 0 0 6 
Verdalles 0 0 1 1 1 1 0 1 1 0 1 1 0 0 1 0 0 0 0 0 1 10 
Williams 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 1 1 0 1 18 
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Supplementary Information 3 
Publication bias 
 
 
Figure S1:  A funnel plot demonstrating the direction and size of effects in Randomised Studies and non-Randomised 
Studies.  
 
 Largest study (Williams, n=335) is at the top of the graph, with a smaller effect size than the mean estimated effect.  
 Note, all the NRS lie to the left of the mean effect estimate. This indicates that the effect of MRA is more beneficial 
in NRS than in RS.  
 The likelihood of publication bias is small for two reasons.  
 First, the most commonly used MRA, spironolactone, is an off-patent medicine and investigators 
would have little financial incentive to not publish negative results. Second, the small study effects are 
likely due to poor methodological quality. Asymmetry in the graph is caused by the distribution of 
NRS. The methodological quality of all the NRS was quite low, as recorded in quality assessment 
forms.  
 
 
